Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Pediatric Blood & Cancer ; 69:S338-S338, 2022.
Article in English | Web of Science | ID: covidwho-2083438
2.
International Joint Conference on Neural Networks (IJCNN) ; 2021.
Article in English | Web of Science | ID: covidwho-1612793

ABSTRACT

Forecasting time series present a perpetual topic of research in statistical machine learning for the last five decades. Due to the unprecedented outbreak of the novel coronavirus (COVID-19), forecasting the COVID-19 pandemic became a key research interest for both epidemiologists and statisticians. These future predictions are useful for the effective allocation of health care resources, stockpiling, and help in strategic planning for clinicians, government authorities, and public-health policymakers. This paper develops an effective forecasting model that can generate real-time short-term (ten days) and long-term (fifty days) out-of-sample forecasts of COVID-19 outbreaks for eight profoundly affected countries, namely the United States of America, Brazil, India, Russia, South Africa, Mexico, Spain, and Iran. A novel hybrid approach based on the Theta method and Autoregressive neural network (ARNN) model, named Theta-ARNN (TARNN) model, is proposed. The proposed method outperforms previously available single and hybrid forecasting models for COVID-19 predictions in most data sets. The ergodicity and asymptotic stationarity of the TARNN model are also studied.

3.
Blood ; 138:1673, 2021.
Article in English | EMBASE | ID: covidwho-1582219

ABSTRACT

Background: Light-chain amyloidosis (AL-A) is a rare, severe, progressive, systemic disorder with high mortality caused by immunoglobulin (Ig) light chains that misfold and aggregate into amyloid fibrils that deposit in multiple organs, leading to progressive organ dysfunction/damage and death. Prognosis is poor for patients with cardiac involvement (characterized by high levels of cardiac troponin T and N-terminal brain natriuretic peptide). Median survival is 24 and 4 months for Mayo Stage IIIa and IIIb AL-A, respectively, based on the 2013 European Modification of the 2004 Mayo Staging system. For most patients, standard of care (SOC) is anti-plasma cell dyscrasia (PCD) therapy to suppress plasma cell proliferation, halt generation of amyloidogenic free light chains, and stop deposition of new amyloid fibrils and further organ decline. However, a critical need exists for therapies that accelerate the removal of deposited fibrils. CAEL-101 is a monoclonal antibody that binds to misfolded Ig light chains in amyloid fibrils. In Phase 1 and 2, CAEL-101 (with and without concurrent PCD SOC) was well tolerated up to 1000 mg/m 2. Preliminary Phase 2 data (NCT04304144) suggest improvements in cardiac and renal biomarkers in some patients. Objective: To evaluate the efficacy and safety of CAEL-101 versus placebo when administered concurrently with SOC anti-PCD therapy in treatment-naïve patients with cardiac AL-A, Mayo Stages IIIb (NCT04504825;Study 1) or IIIa (NCT04512235;Study 2). Methods: These international, multicenter, double-blind, randomized, phase 3 trials, initiated in 2020, are enrolling patients at over 70 sites in 14 countries. Newly diagnosed adults with AL-A stage IIIb or IIIa based on the 2013 European Modification of 2004 Mayo Staging (Wechalekar AD et al. Blood 2013;121:3420. Dispenzieri A, et al. J Clin Oncol. 2004;22:3751), measurable hematologic disease, and histopathological diagnosis of amyloidosis with cardiac involvement are eligible. Patients cannot have any other form of amyloidosis, symptomatic orthostatic hypotension, or supine systolic blood pressure <90 mmHg. Patients in Mayo Stages IIIb (N=111) and IIIa (N=267) are randomized 2:1 to receive once-weekly intravenous infusions of CAEL-101 (1000 mg/m 2) or placebo for 4 weeks, followed by maintenance dosing every 2 weeks. In these event-driven studies, treatment will continue to a minimum of 54 deaths for Study 1 and 77 deaths for Study 2 (a minimum treatment duration of 12 months is expected). Patients will receive concurrent anti-PCD therapy per the institutional protocol for SOC and will be followed to death from any cause or until end of study (Figure). The primary endpoint is overall survival (defined as the time from first dose of study drug to date of death, with censoring at last known living date), and will be analyzed via time-to-event log-rank statistics. Functional, quality of life, and echocardiography measures are targeted secondary endpoints. Results: Patient baseline characteristics and demographics are presented (Table). As of July 17, 2021, 9/13 (69.2%) patients in Study 1 and 23/39 (59%) patients in Study 2 have received at least 4 doses of CAEL-101 concurrently with anti-PCD therapy. Discussion: These ongoing trials will evaluate the efficacy and safety of CAEL-101 as first-in-class treatment to reduce amyloid burden in patients with cardiac AL-A. Notably, Study 1 (Mayo Stage IIIb) is the first randomized, placebo-controlled efficacy clinical trial to formally assess the effects of a pharmacological in this severely ill population. Because the median expected survival for Mayo Stage IIIb patients is far shorter than for Mayo Stage IIIa patients, the resulting sample size required for the Mayo Stage IIIB study is less (111 patients) than for the Mayo Stage IIIA study (267 patients). Importantly, these studies include patients identified as Stage III and IV based on the 2012 Mayo staging system (Kumar S. et al. J Clin Oncol. 2012;30:989). These trials are ongoing in a challenging environment. The approval of daratumumab i 2021 changed the landscape and modified the SOC, requiring appropriate protocol amendments. While the COVID pandemic affected all people, it had a greater impact on patients with AL amyloidosis, a rare disease that can only be treated effectively by a coordinated team of experts at centers of excellence. [Formula presented] Disclosures: Wechalekar: Alexion, AstraZeneca Rare Disease: Consultancy;Caelum Biosciences: Other: Clinical Trial Funding;Janssen: Consultancy;Celgene: Honoraria;Takeda: Honoraria;Amgen: Research Funding. Silowsky: Caelum Biosciences: Current Employment. Daniel: Caelum Biosciences: Current Employment. Harnett: Caelum Biosciences: Current Employment. Spector: Caelum Biosciences: Current Employment. Sobolov: Caelum Biosciences: Current Employment. Quarta: Alexion, AstraZeneca Rare Disease: Current Employment. Kurman: Caelum Biosciences: Other: Medical Monitor. Tulchinskiy: Caelum Biosciences: Consultancy. Bhattacharyya: Alexion, AstraZeneca Rare Disease: Current Employment. Liedtke: Karyopharm: Membership on an entity's Board of Directors or advisory committees;Kite: Membership on an entity's Board of Directors or advisory committees;Celgene: Membership on an entity's Board of Directors or advisory committees;Sanofi: Membership on an entity's Board of Directors or advisory committees;Takeda: Membership on an entity's Board of Directors or advisory committees;GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees;Pfizer: Honoraria;Oncopeptides: Membership on an entity's Board of Directors or advisory committees;Kura Oncology: Membership on an entity's Board of Directors or advisory committees;Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees;Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees;Alnylam: Membership on an entity's Board of Directors or advisory committees;Caelum: Membership on an entity's Board of Directors or advisory committees, Other: Clinical Trial Funding.

4.
Journal of Management in Engineering ; 38(1), 2022.
Article in English | Scopus | ID: covidwho-1475554

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has brought unprecedented impacts (e.g., labor shortage, suspension and cancellation of projects, and disrupted supply and logistics) on the US construction industry. To address challenges caused by the pandemic, it is critical for the construction industry to develop a clear understanding of how the pandemic has affected the industry and how it will change in the future. However, assessing the impacts of COVID-19 on the construction industry is challenging due to the broad influence of the pandemic and the dynamic nature of the industry. The Purdue Index for Construction (Pi-C), which was developed as an indicator based on five dimensions and corresponding metrics to measure the health status of the construction industry, offers an opportunity to understand the impact of the pandemic. In this context, this paper presents a study to reveal the relationship between COVID-19 and the health status of the industry as measured through Pi-C and predict the future trend of the construction industry. This study achieves the objective via the three steps. First, the relationship between the pandemic and Pi-C metrics is identified using the Granger causality test and structural equation modeling (SEM) analysis. Second, multivariable prediction models are developed based on a long short-term memory (LSTM) network - a deep learning algorithm - to predict Pi-C metrics in the future. Third, forecasted Pi-C metrics are integrated into the existing Pi-C structure to analyze the impacts of the COVID-19 pandemic and predict its trends in 2021-2022. The results revealed that the impacts of the pandemic were conspicuous in two Pi-C dimensions (economy and stability), whereas no significant impacts were observed in the remaining Pi-C dimension (social). In addition, the Pi-C forecasted that there would be no significant adverse impacts on the US construction industry caused by the pandemic until the end of 2022. © 2021 American Society of Civil Engineers.

5.
The Journal of the Association of Physicians of India ; 69(7):11-12, 2021.
Article in English | Scopus | ID: covidwho-1431386

ABSTRACT

BACKGROUND: Since its first identification in December 2019, in WUHAN (CHINA), SARS-COV-2, causative agent of Corona virus pandemic, has affected millions of people worldwide, causing thousands of death. There is much speculation about the interplay between ACEI/ARB and Corona virus infection, as for internalization into host cell SARS-COV-2 binds through S spike protein to ACE-2, aided TMPRSS2. METHODS: A record based observational study has been conducted (data obtained from the clinics of fourteen physicians) in two worst affected districts of West Bengal, to find out the association of ACEI/ARB on patients, suffering from Corona virus infection. The study-protocol has already been approved by Clinical Research Ethics Committee of Calcutta School of Tropical Medicine. (IEC Ref. No: CREC-STM/2020-AS-37) Results: Increasing age, male sex and presence of co-morbidities (viz. Diabetes, COPD) are significantly associated with the occurrence of moderate and severe disease. Drugs (viz. ACEI/ARB), though are associated with less severe disease, have not achieved statistical significance, in the present study. CONCLUSION: Drugs, like ACEI/ARB, should be continued in patients suffering from COVID-19 infection, (if they are already on these drugs). © Journal of the Association of Physicians of India 2011.

6.
Journal of Association of Physicians of India ; 69(7):28-33, 2021.
Article in English | Scopus | ID: covidwho-1361002

ABSTRACT

Background: Since its first identification in December 2019, in WUHAN (CHINA), SARS-COV-2, causative agent of Corona virus pandemic, has affected millions of people worldwide, causing thousands of death. There is much speculation about the interplay between ACEI/ARB and Corona virus infection, as for internalization into host cell SARS-COV-2 binds through S spike protein to ACE-2, aided TMPRSS2. Methods: A record based observational study has been conducted (data obtained from the clinics of fourteen physicians) in two worst affected districts of West Bengal, to find out the association of ACEI/ARB on patients, suffering from Corona virus infection. The study-protocol has already been approved by Clinical Research Ethics Committee of Calcutta School of Tropical Medicine. (IEC Ref. No: CREC-STM/2020-AS-37) Results: Increasing age, male sex and presence of co-morbidities (viz. Diabetes, COPD) are significantly associated with the occurrence of moderate and severe disease. Drugs (viz. ACEI/ARB), though are associated with less severe disease, have not achieved statistical significance, in the present study. Conclusion: Drugs, like ACEI/ARB, should be continued in patients suffering from COVID-19 infection, (if they are already on these drugs). © 2021 Journal of Association of Physicians of India. All rights reserved.

7.
International Journal of Health and Allied Sciences ; 9:58-61, 2020.
Article in English | Web of Science | ID: covidwho-1106187

ABSTRACT

Using masks for self-protection has a long history. There are records of the use of masks ranging as far back as the Roman era to Medieval Europe, where masks were used as protective devices. During many festivities, masks were used as a fashion statement. Gas masks were commonly used during the world wars. As pollution started growing, people started using pollution masks. 2020 might be the only era when the entire human population has been forced to wear masks to protect themselves and to protect others. As expected, the healthcare workers, who are leading the fight against the COVID19, are the ones who are most at the need of these devices. Unfortunately, there is a shortage of personal protection equipment all over the world. Hence, we must understand their properties and strengths, and hence that we can achieve maximum benefits from the limited resources.

8.
Indian Journal of Biochemistry & Biophysics ; 57(6):687-693, 2020.
Article in English | Web of Science | ID: covidwho-1001038

ABSTRACT

Pediatric Inflammatory Multisystem Syndrome temporarily associated with SARS-CoV-2 (P1MS-TS) or Multisystem Inflammatory Syndrome in Children (MIS-C) is a post COVID-19 multisystem inflammatory syndrome in children and adolescents <21 years of age. It is slowly emerging in India with clinical features overlapping with Kawasaki Disease (KD) and Toxic Shock Syndrome (TSS). Ten P1MS-TS cases admitted in a pediatric hospital between July and Sept 2020 were compared with 19 Kawasaki Disease (KD) patients' data. The median age of PIMS-TS was 6 years (older to KD), 80% were males. PMS-TS cases had high inflammatory markers: CRP, ferritin, interleukin (IL)-6. Other distinct features were lymphopenia, hypoalbuminemia, and hyponatremia. Serial measurements of CRP showed high baseline values with subsequent decrease. NT-Pro BNP level was extremely elevated;suggestive of cardiac injury. All patients recovered. Laboratory features of P1MS-TS present a unique pattern of intense inflammation, and cardiac involvement that is different from features of pre COVID-19 KD. CRP remains a useful, inexpensive marker for P1MS-TS diagnosis and clinical progression.

SELECTION OF CITATIONS
SEARCH DETAIL